Procter & Gamble Company (The)NYSE: PG
Consumer Staples · Personal Care Products
$147.58
+0.33%
Vol: 10.8M
Research Digest
Friday, May 1, 2026
Procter & Gamble Q3 FY2026 beat estimates with volume growth first time in a year; warned $400M tariff headwind for FY; stock down 1.9%
Procter & Gamble reported Q3 FY2026 sales of $21.235B and net income of $3.932B, beating analyst expectations with first volume growth in a year. Beauty segment outperformed with 7% organic growth. Company announced 70th consecutive dividend increase. However, CFO warned tariffs will cost $400M after-tax this fiscal year and cited Iran war uncertainty. Stock declined 1.9% despite beat due to forward guidance caution. Analyst average PT $163.64.
Previous Market Intelligence
13 daysApr 30Procter Gamble Q3 beats with 7% sales growth to $21.24B, 3% dividend raise; guidance holds amid $1B crude headwindPositive▶
P&G reported FY Q3 (ended Mar 2026) with $21.24B sales (+7% organic), EPS $1.59 (beat estimates), net income $3.93B. Increased dividend 3% (7th consecutive raise, 136th consecutive year of payments). Volume growth first time in a year as categories stabilize. Reiterated full-year guidance: 1-5% sales growth, 1-6% EPS growth. Guides $150M Q4 cost hit from elevated crude; if Brent stays ~$100/barrel, $1B annual after-tax headwind. UBS raised PT to $172 from $166 (Buy); BofA $170 (Buy); TD Cowen $150 (Hold). Stock down 1.9% Apr 29. Risk: commodity cost inflation, category competition, macro slowdown.
Apr 29P&G reports Q3 FY2026 results: revenue $21.2B (+7%), core EPS $1.59 (+3%), announces 70th consecutive dividend increase (+3%), raises some guidancePositive▶
Procter & Gamble delivered strong Q3 FY2026 results on April 24: net sales $21.2B (+7% YoY), organic growth +3%, core EPS $1.59 (+3% YoY). Beauty segment led with 7% organic growth; Personal Care and Skin Care both high single digits. Company raised dividend 3% (70th consecutive annual increase, 136 years of consecutive payments). P&G earned #1 spot on Fortune's 2026 Most Innovative Companies list (3rd consecutive year). Management warned of Iran conflict impact on input costs and consumer spending. FY2026 guidance: sales growth 1-5%, organic growth in-line to +4%. Analyst PTs raised: TD Cowen $142→$150 (Hold); UBS $166→$172.
Apr 16Procter & Gamble lowers guidance; Q2 FY26 EPS beats at $1.88 but revenue misses as tariffs cost $400M after-taxNegative▶
Procter & Gamble reported Q2 fiscal 2026 results with core EPS of $1.88, beating consensus of $1.856, but revenue of $22.208 billion missed the $22.289 billion estimate. Full-year organic sales are up only 2% with core EPS up 3.6%, showing weak growth momentum. Tariff headwinds totaling approximately $400 million in after-tax costs are pressuring earnings. Beauty and Health Care segments grew 5% organically, but the Baby, Feminine and Family Care segment declined 3%. P&G has maintained its dividend king status with 69 consecutive years of increases. Analyst price target cuts: Raymond James lowered target to $170 from $175, and RBC cut to $167 from $172.
Apr 15Procter & Gamble raises dividend 3% to $1.0885 per share, marking 70th consecutive annual increase; stock down 0.73% weeklyNeutral▶
P&G Board approved 3% quarterly dividend increase to $1.0885, extending 70 consecutive years of dividend growth and 136 consecutive years of payouts. Stock declined 0.73% to $144.07. RBC lowered target to $167; Wells Fargo cut to $158. Company strengthening women sports investment with WNBA partnership.
Apr 14Procter & Gamble weakened on analyst downgrades; Q1 earnings April 24Neutral▶
Declined 1.03% to $141.30. RBC Capital cut PT to $167; Wells Fargo to $158. Q1 earnings April 24 with expected EPS $1.57.
Apr 13Procter & Gamble WNBA partnership announced; Q3 earnings April 24; analyst downgradesNeutral▶
P&G announced multi-year WNBA partnership on April 7 spanning Secret, Olay, Tampax, Downy, Gillette Venus, Tide. Q3 earnings webcast April 24 at 8:30 a.m. ET. Goldman Sachs lowered price target from $159 to $155 (neutral); Bank of America cut target from $171 to $167 (maintained buy). Stock trading $144.76-$146.89; down 6.95% month-over-month.
Apr 10Goldman Sachs lowers price target amid economic headwinds, WNBA partnership aims to boost brand relevance.Mixed▶
Procter & Gamble faced analyst headwinds as Goldman Sachs cut its price target from $159 to $155 and TD Cowen lowered from $156 to $142. P&G announced multi-year WNBA partnership with Secret, Olay, Tampax, Downy, Gillette Venus, and Tide. Company rejected unsolicited mini-tender offer from Potemkin Limited at $105/share. Q3 earnings scheduled for April 24. Stock closed at $145.00 after 2.6% gain.
Apr 9Procter & Gamble navigates supply chain headwinds and margin pressuresNeutral▶
Procter & Gamble is navigating a challenging environment with oil-linked input cost inflation and margin pressures noted by TD Cowen. The company reported 2% organic sales growth and 4% core EPS growth in recent results. Recent innovation includes OLAY research on cell adhesion and Dawn brand upgrades. Weak China consumer spending pressures the beauty segment, representing roughly one-fifth of sales. Q1 earnings expected April 24 with modest 1.95% EPS growth projected.
Apr 8P&G faces $1B tariff headwind as UBS lowers price target to $166.Negative▶
UBS decreased P&G target from $170 to $166 maintaining Buy, citing tariff headwinds. P&G experiencing 8% share decline over the past month, faces $1 billion pretax tariff headwind in 2026. Expanding via new WNBA partnership and supply chain overhaul. Q1 2026 earnings April 24 with projected EPS $1.57.
Apr 7Procter & Gamble navigates tariffs and private-label pressure; dividend increase announcement scheduled for April 24.Neutral▶
P&G reported fiscal 2025 net sales of $84.3 billion (2% organic growth) and 4% core EPS growth. Company poised to announce 70th consecutive year of dividend growth in April. Tariff headwinds of $1 billion and renewed private-label competition offset post-pandemic pricing power. New CEO Shailesh Jejurikar driving innovation including paper-based Tide EVO redesign. TD Cowen lowered price target to $142 from $156 citing oil-linked input cost inflation from Iran war. Consensus Buy from 15 analysts targets $170.27. Q3 earnings webcast scheduled for April 24, 2026 at 8:30 a.m. ET. Stock at $143.53.
Apr 6P&G faces $1B tariff headwinds; TD Cowen lowers PT to $142.Negative▶
P&G hit by $1B tariff headwinds and oil-linked input cost inflation. TD Cowen lowered PT to $142 from $156 citing margin pressure. FY2025 net sales $84.3B (+2%), organic growth +2%, core EPS +4%. 2026 leadership transition underway.
Apr 3Procter & Gamble faces tariff headwinds and margin pressure; Q3 2026 earnings on April 24 as analysts lower price targets.Negative▶
P&G reported fiscal Q2 2026 net sales of $84.3B (up 2%) with 2% organic sales growth. The company announced Q3 earnings for April 24. TD Cowen lowered its price target to $142 from $156, citing oil-linked input cost inflation. Deutsche Bank also cut targets to $162 from $171, and Erste Group downgraded to Hold from Buy. However, the consensus is still Buy among 15 analysts with a mean price target of $170.27. P&G is poised to announce its 70th consecutive year of dividend growth in April.
Apr 1Procter & Gamble faces analyst downgrades on input cost inflation and tariff headwinds, with stock down 11% over past month.Negative▶
Procter & Gamble is navigating significant headwinds with TD Cowen cutting price target from $156 to $142 citing oil-linked input cost inflation tied to Iran tensions that PG cannot fully absorb. Deutsche Bank also lowered its target from $171 to $162. The stock declined 5.3% over a 5-day losing streak and is down 11% over the past month. Company reported net sales of $84.3 billion (up 2%) with 2% organic growth but pressured margins. P&G is introducing new OLAY peptide technology and plans earnings discussion on April 24, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PGPROCTER | $147.58 | +0.33% | +3.0% | 20.7x | 0.40 | $342.5B |
| KVUEKENVUE | $17.46 | -0.40% | +1.3% | 14.6x | 0.57 | $33.7B |
| ELESTEE | $79.10 | +3.11% | +8.2% | 25.4x | 1.25 | $27.7B |
| WMTWALMART | $131.84 | -0.07% | +4.0% | 40.2x | 0.66 | $1.05T |
| COSTCOSTCO | $1,012.70 | -0.18% | -0.4% | 45.1x | 0.98 | $450.1B |
| KOCOCA | $78.69 | -0.10% | +2.0% | 22.7x | 0.36 | $338.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.